To evaluate the prognostic value of EASIX in patients with severe acute pancreatitis (SAP).
Approach:
Study Design: A retrospective observational study analyzing 340 SAP patients hospitalized from December 2015 to December 2023.
EASIX Calculation: EASIX was calculated as LDH (U/L) × creatinine (mg/dL) / platelet count (109/L).
Data Analysis: Regression analyses identified mortality predictors, and ROC analysis compared the predictive performance of EASIX and a developed prognostic model.
Key Findings:
Overall mortality rate was 28.82%.
Non-survivors had significantly elevated EASIX levels compared to survivors (p < 0.001).
EASIX was identified as an independent predictor of mortality (p = 0.004).
The predictive model incorporating EASIX achieved an AUC of 0.77, outperforming EASIX alone (AUC = 0.70).
Interpretation:
EASIX is a moderately effective prognostic marker in SAP.
Limitations:
The study is retrospective and may have inherent biases.
External validation of the predictive model is needed before clinical application.
Conclusion:
The developed predictive model incorporating EASIX shows improved accuracy over EASIX alone for mortality risk stratification.
